Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Till Seiler

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Drugs|April 8, 2016
The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to DateTill Seiler, Grit Hutter, Martin Dreyling
Immunotherapy|July 20, 2010
Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategiesTill Seiler, Wolfgang Hiddemann, Martin Dreyling
Seminars in Oncology|April 18, 2006
Risk stratification in chronic lymphocytic leukemiaTill Seiler, Hartmut Döhner, Stephan Stilgenbauer
Blood|August 1, 2002
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemiaAlexander Kröber, Till Seiler, Axel Benner, et al.
Blood|March 22, 2018
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humansKristina Busygina, Janina Jamasbi, Till Seiler, et al.
Blood|December 3, 2005
Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genesDirk Kienle, Axel Benner, Alexander Kröber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaAlexander Kröber, Johannes Bloehdorn, Sebastian Hafner, et al.
Genes, Chromosomes & Cancer|April 19, 2011
Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20Tobias Herold, Vindi Jurinovic, Medhanie Mulaw, et al.
Plos One|September 7, 2013
Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemiaMaria Göbel, Lewin Eisele, Michael Möllmann, et al.
Leukemia & Lymphoma|November 30, 2012
High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signatureTobias Herold, Medhanie A Mulaw, Vindi Jurinovic, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Drugs|April 8, 2016
The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to DateTill Seiler, Grit Hutter, Martin Dreyling
Immunotherapy|July 20, 2010
Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategiesTill Seiler, Wolfgang Hiddemann, Martin Dreyling
Seminars in Oncology|April 18, 2006
Risk stratification in chronic lymphocytic leukemiaTill Seiler, Hartmut Döhner, Stephan Stilgenbauer
Blood|August 1, 2002
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemiaAlexander Kröber, Till Seiler, Axel Benner, et al.
Blood|March 22, 2018
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humansKristina Busygina, Janina Jamasbi, Till Seiler, et al.
Blood|December 3, 2005
Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genesDirk Kienle, Axel Benner, Alexander Kröber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaAlexander Kröber, Johannes Bloehdorn, Sebastian Hafner, et al.
Genes, Chromosomes & Cancer|April 19, 2011
Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20Tobias Herold, Vindi Jurinovic, Medhanie Mulaw, et al.
Plos One|September 7, 2013
Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemiaMaria Göbel, Lewin Eisele, Michael Möllmann, et al.
Leukemia & Lymphoma|November 30, 2012
High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signatureTobias Herold, Medhanie A Mulaw, Vindi Jurinovic, et al.
Pageof 2